CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops arhalofenate, which has completed five Phase II clinical trials for the treatment of patients with gout; and MBX-2982, an oral G-protein coupled receptor agonist that has completed one Phase II clinical trial for therapeutic indications. It has licensing agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States; and Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders, as well as a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-293-8800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10 million
Profitability
Miscellaneous
Employees26
OptionableOptionable
CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions
What is CymaBay Therapeutics' stock symbol?
CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."
How were CymaBay Therapeutics' earnings last quarter?
CymaBay Therapeutics Inc (NASDAQ:CBAY) issued its quarterly earnings results on Friday, August, 10th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.04. View CymaBay Therapeutics' Earnings History.
When is CymaBay Therapeutics' next earnings date?
What price target have analysts set for CBAY?
8 analysts have issued 12 month price objectives for CymaBay Therapeutics' shares. Their predictions range from $9.00 to $30.00. On average, they anticipate CymaBay Therapeutics' stock price to reach $19.8750 in the next year. This suggests a possible upside of 93.1% from the stock's current price. View Analyst Price Targets for CymaBay Therapeutics.
What is the consensus analysts' recommendation for CymaBay Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CymaBay Therapeutics.
What are Wall Street analysts saying about CymaBay Therapeutics stock?
Here are some recent quotes from research analysts about CymaBay Therapeutics stock:
- 1. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (2/6/2019)
- 2. Cantor Fitzgerald analysts commented, ". Reiterate our Overweight rating; increasing 12-mo. PT to $20. CymaBay is a liver disease company with lead asset, seladelpar, in Ph3 for primary biliary cholangitis (PBC). Our checks suggest seladelpar’s strong profile in PBC has the potential to grow the market significantly from where it is today. We think the opportunity in PBC alone (~$350M in 2026 unadjusted sales vs. cap of $500M) should justify upside. We see further potential for seladelpar with a 2Q19 Ph2b NASH proof of concept readout, which could be a much larger opportunity (~ $4B+) for Seladelpar if successful. In our 75-page slide deck, we took a close look at PPAR-delta biology & role in NASH. Our Take: PPAR-delta has the potential to be a major target in the NASH space." (2/1/2019)
Has CymaBay Therapeutics been receiving favorable news coverage?
News stories about CBAY stock have been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CymaBay Therapeutics earned a daily sentiment score of 1.4 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are some of CymaBay Therapeutics' key competitors?
Some companies that are related to CymaBay Therapeutics include Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Heron Therapeutics (HRTX), Insmed (INSM), Madrigal Pharmaceuticals (MDGL), Portola Pharmaceuticals (PTLA), Xencor (XNCR), Enanta Pharmaceuticals (ENTA), Supernus Pharmaceuticals (SUPN), Zogenix (ZGNX), Endocyte (ECYT), Biohaven Pharmaceutical (BHVN), The Medicines (MDCO), AnaptysBio (ANAB) and Mallinckrodt (MNK).
Who are CymaBay Therapeutics' key executives?
CymaBay Therapeutics' management team includes the folowing people:
- Mr. Sujal A. Shah, Pres, CEO & Director (Age 46)
- Dr. Charles A. McWherter, Sr. VP & Chief Scientific Officer (Age 64)
- Dr. Pol F. Boudes, Chief Medical Officer (Age 62)
- Mr. Daniel Menold, VP of Fin. (Age 49)
- Mr. Paul T. Quinlan, Gen. Counsel & Corp. Sec. (Age 56)
Who are CymaBay Therapeutics' major shareholders?
CymaBay Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.68%), Eagle Asset Management Inc. (4.80%), Foresite Capital Management IV LLC (4.43%), Perceptive Advisors LLC (4.14%), Foresite Capital Management III LLC (2.67%) and Great Point Partners LLC (2.39%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Charles Mcwherter, Daniel Menold, Kurt Von Emster, Robert James Wills and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.
Which major investors are selling CymaBay Therapeutics stock?
CBAY stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Perceptive Advisors LLC, Barclays PLC, Eversept Partners LP, MetLife Investment Advisors LLC, Two Sigma Advisers LP, Bank of New York Mellon Corp and New York State Common Retirement Fund. Company insiders that have sold CymaBay Therapeutics company stock in the last year include Carl Goldfischer, Daniel Menold and Kurt Von Emster. View Insider Buying and Selling for CymaBay Therapeutics.
Which major investors are buying CymaBay Therapeutics stock?
CBAY stock was purchased by a variety of institutional investors in the last quarter, including Great Point Partners LLC, BlackRock Inc., Foresite Capital Management IV LLC, Dimensional Fund Advisors LP, Fosun International Ltd, Millennium Management LLC, Westfield Capital Management Co. LP and Bailard Inc.. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter, Robert James Wills and Sujal Shah. View Insider Buying and Selling for CymaBay Therapeutics.
How do I buy shares of CymaBay Therapeutics?
Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CymaBay Therapeutics' stock price today?
One share of CBAY stock can currently be purchased for approximately $10.29.
How big of a company is CymaBay Therapeutics?
CymaBay Therapeutics has a market capitalization of $611.64 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-27,550,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. CymaBay Therapeutics employs 26 workers across the globe.
What is CymaBay Therapeutics' official website?
How can I contact CymaBay Therapeutics?
CymaBay Therapeutics' mailing address is 7999 GATEWAY BLVD SUITE 130, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]
MarketBeat Community Rating for CymaBay Therapeutics (NASDAQ CBAY)
MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe CBAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
